<DOC>
	<DOC>NCT01409343</DOC>
	<brief_summary>This is a prospective, open label, multicenter study evaluating the safety, tolerability and pharmacokinetics of TrasGEX™ after intravenous administration in patients with HER-2 positive cancers. The effect of TrasGEX™ on the development of anti-drug antibodies and on tumour response will also be evaluated.</brief_summary>
	<brief_title>TrasGEX™: Dose Escalation Study</brief_title>
	<detailed_description />
	<criteria>Main 1. Signed written informed consent granted prior to initiation of any studyspecific procedures; 2. Male or female patients of ≥18 years of age; 3. ERBB2 (HER2) gene amplification or ERBB2 overexpression 4. Histologically or cytologically confirmed cancer, either locally advanced or metastatic; 5. No antitumor therapy of proven benefit available at study enrollment; 6. Life expectancy of &gt;=3 months; 7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) &lt;=2; 8. Male or female patients of childproducing potential must agree to use contraceptive measures or oral contraception during the study and for 28 days after the last dose of TrasGEX™; 9. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of TrasGEX™; and Main 1. Anticancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks of the first dose of TrasGEX™; 2. Major surgery within four weeks of the first dose of TrasGEX™; 3. Newly diagnosed brain metastases, metastases that have been documented to be stable for &lt;3 months, or metastases for which systemic corticosteroids are required; 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition as TrasGEX™; 5. History of myocardial infarction within 12 months of the administration of the first dose of TrasGEX™; 6. History of congestive heart failure defined as Class II to IV per New York Heart Association classification within 12 months of the administration of the first dose of TrasGEX™; 7. Left ventricular ejection fraction &lt;50%; 8. Previous malignancy other than the current diagnosis within 5 years of the first dose of TrasGEX™; 9. Pregnancy or lactation; and 10. Concurrent uncontrolled significant illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>advanced solid cancers</keyword>
	<keyword>metastatic solid cancers</keyword>
</DOC>